Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 13/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 12/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 2/20 | 0.40 |
| ▸ | CDK8 | P49336 | 2/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581018 | 0.86 | CYP1A2 (0.48) | CYP2C9NAMPTCCNCCDK8MAPK1 | |
| SCHEMBL4580114 | 0.86 | MAPK8 (0.47) | MAPK8MAPK9MAPK10CYP2C9NAMPT | |
| SCHEMBL15741796 | 0.86 | HPGD (0.44) | CCNCCDK8MAPK1 | |
| SCHEMBL4579300 | 0.86 | SMN1; SMN2 (0.47) | MAPK8MAPK9MAPK10CYP2C9CCNC | |
| SCHEMBL15742715 | 0.85 | CCR1 (0.48) | MAPK8MAPK9MAPK10CYP2C9NAMPT | |
| SCHEMBL4581252 | 0.83 | SLC40A1 (0.43) | MAPK8MAPK9MAPK10NAMPTCCNC | |
| SCHEMBL4580708 | 0.83 | MAPK8 (0.49) | MAPK8MAPK9MAPK10CYP2C9NAMPT | |
| SCHEMBL15742742 | 0.82 | CCNC (0.46) | MAPK8MAPK9MAPK10CYP2C9NAMPT | |
| SCHEMBL15747596 | 0.81 | MAPK8 (0.46) | MAPK8MAPK9MAPK10CYP2C9NAMPT | |
| SCHEMBL15742701 | 0.80 | MAPK8 (0.45) | MAPK8MAPK9MAPK10CYP2C9NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | claimed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| EP-1773834-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | Serenex, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006017672-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | SERENEX INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | MAPK8 2136/4885MAPK9 2109/4885MAPK10 3940/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | MAPK8 2136/4885MAPK9 2109/4885MAPK10 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.